Model Based Targeting of IL-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the JAK Inhibitor Ruxolitinib

IL-6 is a central mediator of the immediate induction of hepatic acute phase proteins (APP) in the liver during infection and after injury, but increased IL-6 activity has been associated with multiple pathological conditions. In hepatocytes, IL-6 activates JAK1-STAT3 signaling that induces the negative feedback regulator SOCS3 and expression of APPs. While different inhibitors of IL-6-induced JAK1-STAT3-signaling have been developed, understanding their precise impact on signaling dynamics requires a systems biology approach. Here we present a mathematical model of IL-6-induced JAK1-STAT3 signaling that quantitatively links physiological IL-6 concentrations to the dynamics of IL-6-induced signal transduction and expression of target genes in hepatocytes. The mathematical model consists of coupled ordinary differential equations (ODE) and the model parameters were estimated by a maximum likelihood approach, whereas identifiability of the dynamic model parameters was ensured by the Profile Likelihood. Using model simulations coupled with experimental validation we could optimize the long-term impact of the JAK-inhibitor Ruxolitinib, a therapeutic compound that is quickly metabolized. Model-predicted doses and timing of treatments helps to improve the reduction of inflammatory APP gene expression in primary mouse hepatocytes close to levels observed during regenerative conditions. The concept of improved efficacy of the inhibitor through multiple treatments at optimized time intervals was confirmed in primary human hepatocytes. Thus, combining quantitative data generation with mathematical modeling suggests that repetitive treatment with Ruxolitinib is required to effectively target excessive inflammatory responses without exceeding doses recommended by the clinical guidelines.

[1]  R. Sabat,et al.  Biology of interleukin-10. , 2010, Cytokine & growth factor reviews.

[2]  Isabelle S. Lucet,et al.  SOCS3 binds specific receptor–JAK complexes to control cytokine signaling by direct kinase inhibition , 2013, Nature Structural &Molecular Biology.

[3]  G. Adler,et al.  The murine liver is a potential target organ for IL-19, IL-20 and IL-24: Type I Interferons and LPS regulate the expression of IL-20R2. , 2007, Journal of hepatology.

[4]  Steffen Klamt,et al.  An integrative model links multiple inputs and signaling pathways to the onset of DNA synthesis in hepatocytes , 2012, The FEBS journal.

[5]  Jens Timmer,et al.  Likelihood based observability analysis and confidence intervals for predictions of dynamic models , 2011, BMC Systems Biology.

[6]  C. Hunter,et al.  IL-6 as a keystone cytokine in health and disease , 2015, Nature Immunology.

[7]  S. Shepard,et al.  Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans , 2010, Drug Metabolism and Disposition.

[8]  V. Poli,et al.  Essential Role of STAT3 in the Control of the Acute-Phase Response as Revealed by Inducible Gene Activation in the Liver , 2001, Molecular and Cellular Biology.

[9]  L. Lovat,et al.  Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. Heinrich,et al.  Hepatic acute phase proteins--regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling. , 2012, European journal of cell biology.

[11]  S. Klamt,et al.  T160‐phosphorylated CDK2 defines threshold for HGF‐dependent proliferation in primary hepatocytes , 2015, Molecular systems biology.

[12]  Jens Timmer,et al.  Driving the Model to Its Limit: Profile Likelihood Based Model Reduction , 2016, PloS one.

[13]  E. Sundberg,et al.  Recruitment of TLR adapter TRIF to TLR4 signaling complex is mediated by the second helical region of TRIF TIR domain , 2013, Proceedings of the National Academy of Sciences.

[14]  J. Wiśniewski,et al.  In-depth quantitative analysis and comparison of the human hepatocyte and hepatoma cell line HepG2 proteomes. , 2016, Journal of proteomics.

[15]  Kevin M. McBride,et al.  STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Bradley,et al.  Agouti C57BL/6N embryonic stem cells for mouse genetic resources , 2009, Nature Methods.

[17]  T. Hirano,et al.  Excessive production of interleukin 6/B cell stimulatory factor‐2 in rheumatoid arthritis , 1988, European journal of immunology.

[18]  M. Tremblay,et al.  The T Cell Protein Tyrosine Phosphatase Is a Negative Regulator of Janus Family Kinases 1 and 3 , 2002, Current Biology.

[19]  N. Hayashi,et al.  STAT3 signaling within hepatocytes is required for anemia of inflammation in vivo , 2010, Journal of Gastroenterology.

[20]  Andreas Kowarsch,et al.  Dynamic mathematical modeling of IL13-induced signaling in Hodgkin and primary mediastinal B-cell lymphoma allows prediction of therapeutic targets. , 2011, Cancer research.

[21]  Hiroaki Ito.  IL-6 and Crohn's disease. , 2003, Current drug targets. Inflammation and allergy.

[22]  K. Rajewsky,et al.  A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. , 1995, Nucleic acids research.

[23]  D. Candinas,et al.  P2X1‐regulated IL‐22 secretion by innate lymphoid cells is required for efficient liver regeneration , 2016, Hepatology.

[24]  Gabriella,et al.  Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. , 2001, Molecular and cellular biology.

[25]  Shinya Kuroda,et al.  Prediction and validation of the distinct dynamics of transient and sustained ERK activation , 2005, Nature Cell Biology.

[26]  K. Karalis,et al.  Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in Apolipoprotein E knockout mice. , 2003, Cardiovascular research.

[27]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[28]  Warren S. Alexander,et al.  A family of cytokine-inducible inhibitors of signalling , 1997, Nature.

[29]  J. Karlsson,et al.  Modeling the Dynamics of Acute Phase Protein Expression in Human Hepatoma Cells Stimulated by IL-6 , 2015 .

[30]  H. Kantarjian,et al.  Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. , 2010, Blood.

[31]  N A W van Riel,et al.  Parameter uncertainty in biochemical models described by ordinary differential equations. , 2013, Mathematical biosciences.

[32]  C. Trautwein,et al.  Contribution of interleukin-6/gp 130 signaling in hepatocytes to the inflammatory response in mice infected with Streptococcus pyogenes. , 2007, The Journal of infectious diseases.

[33]  Elizabeta Nemeth,et al.  Hepcidin and iron homeostasis. , 2012, Biochimica et biophysica acta.

[34]  J. Scheller,et al.  Early hepatocyte DNA synthetic response posthepatectomy is modulated by IL-6 trans-signaling and PI3K/AKT activation. , 2011, Journal of hepatology.

[35]  N. Macdonald,et al.  Time delay in simple chemostat models , 1976, Biotechnology and bioengineering.

[36]  D B Kell,et al.  Oscillations in NF-kappaB signaling control the dynamics of gene expression. , 2004, Science.

[37]  K. Olthoff,et al.  Interleukin‐6 from intrahepatic cells of bone marrow origin is required for normal murine liver regeneration , 2002, Hepatology.

[38]  C. Schindler,et al.  Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. , 1994, Science.

[39]  Bianca Sperl,et al.  Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. , 2006, Chemistry & biology.

[40]  Ashley M Miller,et al.  The jackknife---a review , 1974 .

[41]  A. Simon,et al.  Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[42]  S. Polyak,et al.  Molecular Pathways: Hepatitis C Virus, CXCL10, and the Inflammatory Road to Liver Cancer , 2013, Clinical Cancer Research.

[43]  P Franchimont,et al.  Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. , 1992, Annals of surgery.

[44]  N. Copeland,et al.  A highly efficient recombineering-based method for generating conditional knockout mutations. , 2003, Genome research.

[45]  J. Timmer,et al.  Experimental Design for Parameter Estimation of Gene Regulatory Networks , 2012, PloS one.

[46]  P. Heinrich,et al.  Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding. , 1993, The Journal of biological chemistry.

[47]  G. Fantuzzi,et al.  Defective inflammatory response in interleukin 6-deficient mice , 1994, The Journal of experimental medicine.

[48]  T. Hirano,et al.  Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation. , 1996, The EMBO journal.

[49]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[50]  Yukiko Matsuoka,et al.  Using process diagrams for the graphical representation of biological networks , 2005, Nature Biotechnology.

[51]  Melanie Boerries,et al.  Protein abundance of AKT and ERK pathway components governs cell type‐specific regulation of proliferation , 2017, Molecular systems biology.

[52]  H. Gascan,et al.  Interleukin-33 overexpression is associated with liver fibrosis in mice and humans , 2009, Journal of cellular and molecular medicine.

[53]  K. Eguchi,et al.  Involvement of IL-1beta and IL-10 in IFN-alpha-mediated antiviral gene induction in human hepatoma cells. , 2002, Biochemical and biophysical research communications.

[54]  C. Beglinger,et al.  Specific activation of AP‐1 but not Stat3 in regenerating liver in mice , 1997, European journal of clinical investigation.

[55]  S. Shepard,et al.  Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction. , 2009, Organic letters.

[56]  J. Darnell,et al.  Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors , 1995, Science.

[57]  J. Sirard,et al.  IL‐22 is produced by γC‐independent CD25+ CCR6+ innate murine spleen cells upon inflammatory stimuli and contributes to LPS‐induced lethality , 2011, European journal of immunology.

[58]  L. Chiriboga,et al.  Intrahepatic levels of CXCR3‐associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C , 2008, Hepatology.

[59]  K. Eguchi,et al.  Involvement of IL-1β and IL-10 in IFN-α-mediated antiviral gene induction in human hepatoma cells , 2002 .

[60]  A. Jayaraman,et al.  Modeling regulatory mechanisms in IL‐6 signal transduction in hepatocytes , 2006, Biotechnology and bioengineering.

[61]  P. Kivisäkk,et al.  Increased interleukin-6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis , 1996, Journal of Neuroimmunology.

[62]  T. Maiwald,et al.  Materials and Methods SOM Text Figs. S1 to S16 References Materials and Methods , 2022 .

[63]  Martin E. Böhm,et al.  One‐source peptide/phosphopeptide standards for accurate phosphorylation degree determination , 2011, Proteomics.

[64]  Tetsuya Yamamoto,et al.  The nuclear isoform of protein-tyrosine phosphatase TC-PTP regulates interleukin-6-mediated signaling pathway through STAT3 dephosphorylation. , 2002, Biochemical and biophysical research communications.

[65]  P. Heinrich,et al.  Janus Kinase (Jak) Subcellular Localization Revisited , 2004, Journal of Biological Chemistry.

[66]  J. Timmer,et al.  Supporting Online Material Material and Methods , 2022 .

[67]  D. Swinkels,et al.  Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. , 2005, Blood.

[68]  T. Hirano,et al.  Regulation of synthesis and secretion of major rat acute-phase proteins by recombinant human interleukin-6 (BSF-2/IL-6) in hepatocyte primary cultures. , 1988, European journal of biochemistry.

[69]  Donald Metcalf,et al.  SOCS3 negatively regulates IL-6 signaling in vivo , 2003, Nature Immunology.

[70]  P. Brandtzaeg,et al.  Brief Definitive Report the Complex Pattern of Cytokines in Serum from Patients with Meningococcal Septic Shock Association between Interleukin 6, Interleukin 1, and Fatal Outcome , 2022 .

[71]  Fabian J. Theis,et al.  Data2Dynamics: a modeling environment tailored to parameter estimation in dynamical systems , 2015, Bioinform..

[72]  Martin Mönnigmann,et al.  Model-driven experimental analysis of the function of SHP-2 in IL-6-induced Jak/STAT signaling. , 2012, Molecular bioSystems.

[73]  V. Grantcharova,et al.  Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.

[74]  D. Lawlor,et al.  Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. , 2008, European journal of cancer.

[75]  Jens Schneider-Mergener,et al.  SHP2 and SOCS3 Contribute to Tyr-759-dependent Attenuation of Interleukin-6 Signaling through gp130* , 2003, The Journal of Biological Chemistry.

[76]  S. Dooley,et al.  Primary mouse hepatocytes for systems biology approaches: a standardized in vitro system for modelling of signal transduction pathways. , 2006, Systems biology.

[77]  M. Mönnigmann,et al.  Nucleocytoplasmic shuttling of persistently activated STAT3 , 2007, Journal of Cell Science.

[78]  J. Timmer,et al.  Division of labor by dual feedback regulators controls JAK2/STAT5 signaling over broad ligand range , 2011, Molecular systems biology.

[79]  P. Heinrich,et al.  40 INTERLEUKIN-6 SIGNALING DURING THE ACUTE-PHASE RESPONSE OF THE LIVER , 2009 .

[80]  J Timmer,et al.  Quantitative data generation for systems biology: the impact of randomisation, calibrators and normalisers. , 2005, Systems biology.

[81]  A. Jayaraman,et al.  Investigation of IL-6 and IL-10 signalling via mathematical modelling. , 2011, IET systems biology.

[82]  S. Akira,et al.  IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages , 2003, Nature Immunology.

[83]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[84]  R. Norton,et al.  Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. , 2012, Immunity.

[85]  A. Miyajima,et al.  Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice , 2004, Hepatology.

[86]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[87]  A. Norrby-Teglund,et al.  Correlation between serum TNF alpha and IL6 levels and severity of group A streptococcal infections. , 1995, Scandinavian journal of infectious diseases.

[88]  N. Andrews,et al.  Interleukin-6 induces hepcidin expression through STAT3. , 2006, Blood.

[89]  M. Karin,et al.  Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage , 2011, Annals of the rheumatic diseases.

[90]  Steve E. Calvano,et al.  Acute Inflammatory Response to Endotoxin in Mice and Humans , 2005, Clinical Diagnostic Laboratory Immunology.

[91]  Jens Timmer,et al.  Systems-level interactions between insulin–EGF networks amplify mitogenic signaling , 2009, Molecular systems biology.

[92]  Christian Trautwein,et al.  STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. , 2007, Gastroenterology.

[93]  U. Alon,et al.  Robustness in bacterial chemotaxis , 2022 .

[94]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[95]  P. Scherle,et al.  The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers , 2011, Journal of clinical pharmacology.

[96]  R. Zinkernagel,et al.  Impaired immune and acute-phase responses in interleukin-6-deficient mice , 1994, Nature.

[97]  William W. Chen,et al.  Classic and contemporary approaches to modeling biochemical reactions. , 2010, Genes & development.

[98]  Marianthi Markatou,et al.  Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. , 2009, The Journal of infectious diseases.

[99]  A. Fontana,et al.  Interleukin-6 is elevated in plasma in multiple sclerosis , 1991, Journal of Neuroimmunology.

[100]  P. Murray.  Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. , 2006, Current opinion in pharmacology.

[101]  J Fernando Bazan,et al.  IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. , 2005, Immunity.

[102]  V. Pascual,et al.  Macrophages induce differentiation of plasma cells through CXCL10/IP-10 , 2012, The Journal of experimental medicine.

[103]  M. Griesshammer,et al.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera. , 2015, The New England journal of medicine.

[104]  U Klingmüller,et al.  Predictive mathematical models of cancer signalling pathways , 2012, Journal of internal medicine.

[105]  H. Willenbring,et al.  A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice , 2008, Nature Protocols.

[106]  T. Calandra,et al.  High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. , 1991, The American journal of medicine.

[107]  James R. Johnson,et al.  Oscillations in NF-κB Signaling Control the Dynamics of Gene Expression , 2004, Science.

[108]  K. Tsumoto,et al.  Interleukin-11 Links Oxidative Stress and Compensatory Proliferation , 2012, Science Signaling.

[109]  V. Subramaniam,et al.  Analysis of IL-22 contribution to hepcidin induction and hypoferremia during the response to LPS in vivo. , 2015, International immunology.

[110]  Wei Wei,et al.  Enhanced liver regeneration in IL-10-deficient mice after partial hepatectomy via stimulating inflammatory response and activating hepatocyte STAT3. , 2011, The American journal of pathology.

[111]  E. Furth,et al.  Liver Failure and Defective Hepatocyte Regeneration in Interleukin-6-Deficient Mice , 1996, Science.

[112]  T. Zimmers,et al.  Resolving the role of IL‐6 in liver regeneration , 2003, Hepatology.

[113]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[114]  G. Miller,et al.  Interleukin 17-producing γδT cells promote hepatic regeneration in mice. , 2014, Gastroenterology.

[115]  Xiaodan Ren,et al.  IL-22 is involved in liver regeneration after hepatectomy. , 2010, American journal of physiology. Gastrointestinal and liver physiology.

[116]  T. Hirano,et al.  Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 , 1989, Cell.

[117]  Sebastian Bohl,et al.  Computational processing and error reduction strategies for standardized quantitative data in biological networks , 2005, The FEBS journal.

[118]  N. Reich,et al.  Tracking STAT nuclear traffic , 2006, Nature Reviews Immunology.

[119]  A. Demetris,et al.  Mitosis and apoptosis in the liver of interleukin‐6–deficient mice after partial hepatectomy , 1999, Hepatology.

[120]  C. Trautwein,et al.  Molecular Dissection of gp130-dependent Pathways in Hepatocytes during Liver Regeneration* , 2008, Journal of Biological Chemistry.

[121]  Ruxolitinib , 2019, Reactions Weekly.

[122]  D. Lauffenburger,et al.  Physicochemical modelling of cell signalling pathways , 2006, Nature Cell Biology.

[123]  J V Castell,et al.  Interleukin-6 and the acute phase response. , 1990, The Biochemical journal.

[124]  Marianthi Markatou,et al.  Peripheral CXCR 3-Associated Chemokines as Biomarkers of Fibrosis in Chronic Hepatitis C Virus Infection , 2009 .

[125]  M. Loda,et al.  Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. , 2002, Blood.

[126]  M. Schilling,et al.  Context-specific flow through the MEK/ERK module produces cell- and ligand-specific patterns of ERK single and double phosphorylation , 2016, Science Signaling.

[127]  J. Timmer,et al.  Identification of nucleocytoplasmic cycling as a remote sensor in cellular signaling by databased modeling , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[128]  One-source peptide/phosphopeptide ratio standards for accurate and site-specific determination of the degree of phosphorylation. , 2014, Methods in molecular biology.